



Addex Pharmaceuticals

First Half 2011 Financial Results

July 27, 2011

Disclaimer

These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities.

These materials contain forward-looking statements based on the currently held beliefs and assumptions of the management of Addex Pharmaceuticals Ltd, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Addex Pharmaceuticals Ltd, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. Addex Pharmaceuticals Ltd disclaims any obligation to update these forward-looking statements to reflect future events or developments.

These materials are strictly confidential and must not be disclosed or distributed to third parties.

Corporate overview

- Focused on the development of allosteric modulators
- Proprietary discovery platform
 - 70,000+ compound allostery-biased library
 - Patented high throughput screening/optimisation systems
- Collaborations with Merck and J&J
- Lead compounds: dipraglurant-IR & ADX71149
 - Dipraglurant-IR Phase IIa PD-L1D started 1Q11
 - Study supported by Michael J. Fox Foundation for Parkinson's Research
 - Data 1H12
 - OMJPI started ADX71149 Phase IIa schizophrenia study 1Q11

Pipeline

| | | | Preclinical | | | Clinical | | |
|-------------------------------|---|---|-------------|-------------------|--------------------|----------|-----------|---------------------------------|
| Partner | Molecule / Mechanism | Assay Development & Screening | Hit-to-Lead | Lead Optimization | Clinical Candidate | Phase I | Phase IIa | Milestone |
| | Dipraglurant-IR (ADX48621) mGluR5 NAM | Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID) partially funded by The Michael J. Fox Foundation | | | | | | Ph II data 1H12 |
| | Dipraglurant-ER (ADX48621) mGluR5 NAM | Dystonia | | | | | | |
| Janssen Pharmaceuticals, Inc. | ADX71149 mGluR2 PAM | Schizophrenia | | | | | | |
| | | funded & developed by JPI* Anxiety | | | | | | |
| | FSHR/LHR NAM | Endometriosis | | | | | | |
| | GABA-BR PAM | Pain | | | | | | |
| | mGluR2 NAM | Alzheimer's / Depression | | | | | | |
| Merck & Co., Inc. | mGluR4 PAM | Parkinson's Disease ‡ | | | | | | CNS |
| | mGluR7 NAM | Depression Generalized Anxiety Disorder | | | | | | |
| | mGluR5 PAM | Schizophrenia ‡ | | | | | | |
| | Receptor tyrosine kinase superfamily (TrkB) | Neurodegenerative & other diseases | | | | | | |
| | GLP1R PAM | Type II Diabetes | | | | | | Metabolism & Inflammation |
| | TNF receptor superfamily (TNFR1 NAM) | Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease Alzheimer's, Multiple Sclerosis | | | | | | |
| | A2A PAM | Psoriasis, Osteoarthritis | | | | | | |
| | Interleukin receptor family (IL-1R1 NAM) | | | | | | | |

NAM = negative allosteric modulator (an inhibitor)
PAM = positive allosteric modulator (an activator)

‡ and undisclosed additional indications

* Janssen Pharmaceuticals, Inc., formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Financial Highlights

- Cash used: CHF13.6 million (in line with guidance)
- Cash as of June 30, 2011: CHF50.2 million
(31/12/2010: CHF63.8m)
- Income: CHF3.2 million
(H1 2010: CHF2.7m)
- Net loss reduced by 14% to CHF14.6 million
(H1 2010: CHF17.3m)
- Headcount: 111.8 FTE as of June 30, 2011

First Half 2011

Consolidated Balance Sheets

| In CHF thousands | Jun 30, 2011 | Dec 31, 2010 | Comments |
|--|-----------------|-----------------|---|
| Cash and cash equivalents | 50'230 | 63'797 | Cost of operations |
| Other current assets | 2'838 | 2'698 | Prepayments |
| Property, plant and equipment | 5'411 | 6'668 | Annual depreciation charge; no significant capex in H1 2011 |
| Other non-current assets | 1'065 | 1'121 | Lease guarantee, employee loans & intangibles |
| Total assets | 59'544 | 74'284 | |
| Payables and accruals | 8'672 | 8'982 | Primarily staff costs & clinical costs |
| Deferred income | 273 | 295 | Merck agreement & MJFF installments |
| Non-current liabilities | 785 | 593 | IAS 19 pension obligation |
| Shareholders' equity | 49'814 | 64'414 | Net loss |
| Total liabilities & s/holders' equity | 59'544 | 74'284 | |

First Half 2011

Consolidated Income Statements


| In CHF thousands | H1 2011 | H1 2010 | Var.(%) | Comments |
|--|-----------------|-----------------|--------------|--|
| Revenue from collaborations | 2'721 | 1'056 | 257% | €2M Phase 2 start milestone from OMJP & Merck mGluR4PAM fees |
| Other income | 452 | 1'644 | (73%) | 2011 French research tax credit & MJFF grant |
| Total income | 3'173 | 2'700 | 18% | |
| R&D expenses | (14'558) | (16'686) | (13%) | Reduced headcount |
| G&A expenses | (3'299) | (3'289) | - | Reduced headcount offset by certain restructuring provisions |
| Operating loss | (14'684) | (17'275) | (15%) | |
| Finance result, net | (143) | 13 | - | Interest income offset by financial exchange differences (EUR/CHF) |
| Net loss for the period | (14'827) | (17'262) | (14%) | |
| Basic and diluted loss per share (CHF) | (2.07) | (3.01) | (31%) | |

First Half 2011

Consolidated Cash Flow Statements

| In CHF thousands | H1 2011 | H1 2010 | Var.(%) | Comments |
|--|-----------------|-----------------|--------------|---|
| Cash at beginning of the period | 63'797 | 76'560 | (17%) | |
| Cash used in operating activities | (15'718) | (19'987) | (21%) | Cost of 2011 operations |
| Cash from collaborations | 2'563 | 485 | 428% | EUR2M Phase 2 start milestone from OMJP |
| Cash used in investing activities | (23) | (222) | (90%) | Reduced investment PPE |
| Cash used in financing activities | (171) | (7) | - | Cost of share capital issuance |
| Net cash used | (13'349) | (19'731) | (32%) | |
| Exchange loss on cash | (218) | (142) | 54% | Strength of CHF vs EUR |
| Cash at end of the period | 50'230 | 56'687 | (11%) | |

Headcount Development



Comments

- YoY headcount reduction of 17% (23.2 FTE)
- Restructuring expected to result in a headcount of 82 FTE by 30th September

Financial Outlook

- 2011 cash utilization guidance of CHF28-32 million
- Cash reach extended from Q1 2013 to Q4 2013
 - Assumption: no cash flows from new partnerships or contingent milestones under existing agreements
- Impact of restructuring:
 - One off charge in H2 2011 of CHF1.7m
 - Annual savings of CHF8m per year starting in 2012

allosteric modulators for human health

tell us which targets interest you !

www.addexpharma.com